Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.).
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
Mol Pharmacol. 2018 Apr;93(4):288-296. doi: 10.1124/mol.117.110395. Epub 2018 Jan 24.
G-protein-coupled receptors (GPCRs) mediate multiple signaling pathways in the cell, depending on the agonist that activates the receptor and multiple cellular factors. Agonists that show higher potency to specific signaling pathways over others are known as "biased agonists" and have been shown to have better therapeutic index. Although biased agonists are desirable, their design poses several challenges to date. The number of assays to identify biased agonists seems expensive and tedious. Therefore, computational methods that can reliably calculate the possible bias of various ligands ahead of experiments and provide guidance, will be both cost and time effective. In this work, using the mechanism of allosteric communication from the extracellular region to the intracellular transducer protein coupling region in GPCRs, we have developed a computational method to calculate ligand bias ahead of experiments. We have validated the method for several -arrestin-biased agonists in -adrenergic receptor (2AR), serotonin receptors 5-HT1B and 5-HT2B and for G-protein-biased agonists in the -opioid receptor. Using this computational method, we also performed a blind prediction followed by experimental testing and showed that the agonist carmoterol is -arrestin-biased in 2AR. Additionally, we have identified amino acid residues in the biased agonist binding site in both 2AR and -opioid receptors that are involved in potentiating the ligand bias. We call these residues functional hotspots, and they can be used to derive pharmacophores to design biased agonists in GPCRs.
G 蛋白偶联受体 (GPCRs) 根据激活受体的激动剂和多种细胞因子,介导细胞内的多种信号通路。与其他信号通路相比,对特定信号通路显示更高效力的激动剂被称为“偏向激动剂”,并已被证明具有更好的治疗指数。尽管偏向激动剂是理想的,但它们的设计迄今为止仍存在一些挑战。鉴定偏向激动剂的测定数量似乎既昂贵又繁琐。因此,能够在实验之前可靠地计算各种配体可能的偏向性并提供指导的计算方法将具有成本效益和时间效益。在这项工作中,我们使用 GPCR 中从细胞外区域到细胞内转导蛋白偶联区域的变构通讯机制,开发了一种在实验之前计算配体偏向性的计算方法。我们已经针对β-肾上腺素能受体 (2AR)、5-羟色胺受体 5-HT1B 和 5-HT2B 中的几个β-arrestin 偏向激动剂以及在 μ-阿片受体中的 G 蛋白偏向激动剂验证了该方法。使用这种计算方法,我们还进行了盲法预测,随后进行了实验测试,并表明激动剂 carmoterol 在 2AR 中是β-arrestin 偏向性的。此外,我们还确定了 2AR 和 μ-阿片受体中偏向激动剂结合位点中的氨基酸残基,这些残基参与增强配体偏向性。我们称这些残基为功能热点,可以用于设计 GPCR 中的偏向激动剂。